Your browser version may not work well with NCBI's Web applications. More information here...
1: Eur Urol. 2006 Jun;49(6):987-97. Epub 2006 Mar 20.Click here to read Links
Comment in:
Eur Urol. 2006 Jun;49(6):946-7.

A critical analysis of nonsurgical treatment of Peyronie's disease.

Hauck EW, Diemer T, Schmelz HU, Weidner W.

Department of Urology and Pediatric Urology, University Clinic Giessen and Marburg, Justus Liebig University Giessen, Germany. ekkehard.w.hauck@chiru.med.uni-giessen.de

OBJECTIVE: Because the efficacy of nonsurgical therapy of Peyronie's disease is controversial, this review analyses the current status of conservative therapy of Peyronie's disease. METHOD: A systematic survey on results of studies published as original papers in peer-reviewed journals is provided. RESULTS: Oral drug therapies include potassium para-aminobenzoate (Potaba), vitamin E, colchicine, tamoxifen, propoleum, acetyl-L-carnitine, and propionyl-L-carnitine. Verapamil, interferon-alpha2a and interferon-alpha2b, collagenase, cortisone, hyaluronidase, and superoxide dismutase are considered intralesional therapies that have had various degrees of success. Other treatments include local gels, iontophoresis, extracorporeal shock wave therapy, and radiation. CONCLUSION: This review analyses the current status of the conservative therapy of Peyronie's disease, because the efficacy of the nonsurgical therapy is controversial.

PMID: 16698449 [PubMed - indexed for MEDLINE]

Patient Drug Information